Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

NCT02711228 | Completed Phase 4

• 2 other identifiers: IgPro20_40052015-004977-34
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of the study is to assess the impact of immunoglobulin treatment by subcutaneous injections every 2 weeks (biweekly) on a cohort of patients with primary and secondary immune deficiencies. The full study will consist of safety, efficacy and Quality of Life (QoL) evaluations and a pharmacokinetic (PK) sub-study. The primary objectives of the study are to determine tolerability and safety of biweekly IgPro20 injection regimen and to compare PK outcomes on weekly and biweekly IgPro20 therapy. Patients who have received and/or are currently receiving immunoglobulin G (IgG) in intravenous (IVIg), or subcutaneous (SCIg) infusions are eligible for inclusion if they meet inclusion/exclusion criteria. The study consists of two parts. In Part 1 of the study enrolled subjects will receive IgPro20 weekly for either 12 weeks (for patients on SCIg infusion prior to the study) or 24 weeks (for patients on IVIg infusion prior to the study). Part 2 will consist of a biweekly treatment with IgPro20 for 52 weeks, for both groups. Additionally, study subjects meeting inclusion criteria for the PK sub-study will undergo a PK sample collection for 1 week and 2 weeks in study Parts 1 and 2, respectively.

Conditions

Primary Immune Deficiency; Secondary Immune Deficiency

Outcome Measures

Primary Outcomes (5)

• Annualized rate of adverse events (local and systemic)

  During biweekly treatment period, up to approximately 52 weeks

• Area under the concentration-time curve, AUC(0-t )

  Immediately before, and up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

• Maximal serum IgG concentration (Cmax)

  Up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

• Time to maximal serum IgG concentration (Tmax)

  Up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

• Trough serum IgG concentration (Ctrough)

  Immediately before, and up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

Secondary Outcomes (3)

• Annualized rate of infections per patient

  During weekly and biweekly treatment periods, up to approximately 64 - 76 weeks

• Serum IgG trough levels (Ctrough)

  On day 7 (immediately before each next infusion) during the weekly treatment period, and on week 24 and 48 of biweekly treatment.

• Health-related Quality of Life

  During weekly and biweekly treatment periods, up to approximately 64 - 76 weeks

Study Arms (1)

Subcutaneous Immune Globulin (Human) (Hizentra)

EXPERIMENTAL

Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.

Biological: Subcutaneous Immune Globulin (Human) (Hizentra)

Interventions

Subcutaneous Immune Globulin (Human) (Hizentra) BIOLOGICAL

Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.

Also known as: IgPro20, Hizentra

Subcutaneous Immune Globulin (Human) (Hizentra)

Eligibility Criteria

• Age: 5 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Full study:
• Female or male patients with primary or secondary immunodeficiency, aged from 5 to 64 years, receiving steady state immunoglobulin G replacement therapy.
• Pharmacokinetic sub-study:
• Female or male patients with primary immunodeficiency, aged between 12 and 64 years of age, on steady-state IgPro20 replacement therapy and willing to undergo pharmacokinetic sample collection on weekly and biweekly IgPro20 dosing regimens.

You may not qualify if:

• Patients with protein losing conditions such as: lymphangiectasis, nephrosis, status post cardio-thoracic surgery requiring drainage tubes for more than 48 hours, protein-losing enteropathy.
• Concomitant treatment with plasma or other blood products (including any IgGs other than IgPro20 \[Hizentra\]) within 21 days before study entry and/or during the study.
• Any other condition or treatment that, in the opinion of the investigator, would interfere with obtaining valid results for that subject.
• Women of childbearing potential with a positive pregnancy test.
• Active infection at the time of screening.

Sponsors & Collaborators

• CSL Behring: lead

Study Sites (2)

Centre Hospitalier de l'université de Montréal

Montreal, QC H2W 1T7, Canada

Location

CHU Sainte-Justine

Montreal, QC H3T 1C4, Canada

Location

MeSH Terms

Conditions

Primary Immunodeficiency Diseases

Interventions

Hizentra

Condition Hierarchy (Ancestors)

Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Elie Haddad, MD

  St. Justine's Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 7, 2016
• First Posted: March 17, 2016
• Study Start: March 15, 2016
• Primary Completion: January 30, 2018
• Study Completion: January 30, 2018
• Last Updated: February 26, 2018

Record last verified: 2018-02

Locations

CA (2)